Touchlight Highlights dbDNA Performance Gains in Lentiviral Vector Manufacturing

According to a recent LinkedIn post from Touchlight, the company is drawing attention to a new blog discussing lentiviral vector production bottlenecks in cell and gene therapy. The post highlights limitations of traditional plasmid DNA manufacturing, including extended timelines, variability, and complex production processes.

The post indicates that Touchlight’s enzymatic dbDNA platform, used in collaboration with Expression Manufacturing, demonstrated up to 40% higher infectious titres for a clinical-stage ET3 transgene. It also suggests consistent performance across both 2.5th- and 3rd-generation lentiviral vector systems, implying potential process robustness.

For investors, the content points to Touchlight’s efforts to position dbDNA as an enabling technology to streamline lentiviral vector production and shorten time to clinic for gene therapy developers. If these performance gains are validated broadly, Touchlight could strengthen its competitive standing in the gene therapy manufacturing supply chain and enhance its appeal as a partner to biopharma companies.

More efficient and scalable vector production platforms are strategically important as cell and gene therapies advance through the clinic and into commercialization. The post therefore may signal that Touchlight is targeting high-value segments of the advanced therapies market, where improved yields and reliability could translate into recurring revenue from technology licensing and manufacturing collaborations.